User talk:Kofod
Hi
I'm Kasper Kofod, Social Media Manager at Novo Nordisk.
Insulin degludec
[edit]Hi Kofod! I've fixed the dosing scheme in the article Insulin degludec. You know, you can just be bold and edit articles yourself instead of waiting for others to do it. Feel free to ask me for help with editing Wikipedia articles. Cheers, ἀνυπόδητος (talk) 08:37, 29 September 2014 (UTC)
Thanks ἀνυπόδητος. And thanks for encouraging us to be bold and edit articles ourselves, but we do not edit articles directly in the article for legal reasons. We have a few more recommendations for corrections with references to support them.
- Suggested corrections to the article:
- Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba[1]. It is administered via subcutaneous injection once daily to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 40 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making insulin degludec a once-daily basal insulin for all patients. [2] [3]
References:
- ^ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002498/human_med_001609.jsp&mid=WC0b01ac058001d124
- ^ Klein et al “Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability. Diabetes Obes Metab 2007 May;9(3):290-9
- ^ Haahr H et Heise T: “A review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance” Clin Pharmacokinet (2014) 53:787-800
- Would you be able to review the corrections and make the changes to the article?
Kofod (talk) Kasper Kofod 14:39, 25 February 2015 (UTC)
Done, thanks for the suggestion. I omitted "for all patients" as that seems a borderline advert phrase to me. (Maybe I'm a bit nitpicky.) Cheers, ἀνυπόδητος (talk) 08:15, 8 March 2015 (UTC)
